anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: While decreased time to fixation in femur fractures improves mortality, it remains unclear if the same relationship exists for pelvic fractures. The National Trauma Data Bank (NTDB) is a data repository for trauma hospitals in the United States (injury characteristics, perioperative data, procedures, 30-day complications), and we used this to investigate early, significant complications after pelvic-ring injuries.
METHODS: The NTDB (2015-2016) was queried to capture operative pelvic ring injuries in adult patients with injury severity score (ISS) ≥ 15. Complications included medical and surgical complications, as well as 30-day mortality. Multivariable logistic regression was used to investigate the association between days to procedure and complications after adjusting for demographic characteristics and comorbidities.
RESULTS: 2325 patients met inclusion criteria. 532 (23.0%) sustained complications, and 72 (3.2%) died within the first 30 days. The most common complications were deep vein thrombosis (DVT) (5.7%), acute kidney injury (AKI) (4.6%), and unplanned intensive care unit (ICU) admission (4.4%). In a multivariate analysis, days to procedure was independently significantly associated with complications, with an adjusted odds ratio (95% confidence interval) of 1.06 (1.03-1.09, P < 0.001), best interpreted as a 6% increase in the odds of complication or death for each additional day.
CONCLUSION: Time to pelvic fixation is a significant and modifiable risk factor for major complications and death. This suggests we should prioritize time to pelvic fixation on trauma patients to minimize mortality and major complications.
OBJECTIVES: A newly discovered adipokine known asprosin in serum and saliva in patients with periodontitis has not been explored. The aim of this study was to determine the relationship between serum and saliva asprosin levels and periodontitis by grouping it according to body mass index (BMI).
MATERIALS AND METHODS: The study was conducted on 65 systemically healthy patients (35 patients with periodontitis (periodontitis group), 30 periodontally healthy patients (control group)). In each patient, age, BMI, and clinical periodontal parameters (plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment level (CAL)) were evaluated. Statistical analyses were conducted utilizing the Student t-test, ANOVA, and Pearson correlation analysis. For the significance level of the tests, p<0.05 were accepted.
RESULTS: The serum and saliva were collected to assess asprosin levels. Both the serum and saliva asprosin levels were statistically significantly higher in the periodontitis group than in the control group (p<0.001). Saliva and serum asprosin levels were directly proportional to the severity of the periodontal disease (p<0.05). Asprosin levels were higher in patients with a higher BMI (p<0.05).
CONCLUSION: Asprosin levels were increased in periodontitis, and even a high BMI status apparently affected the levels of this hormone. It is thought that asprosin may be a useful biomarker in evaluating the relationship between periodontal status and BMI.
CLINICAL RELEVANCE: Asprosin may be a useful parameter as a biomarker of periodontal disease progression. However, BMI status should be considered when evaluating asprosin levels in patients with periodontitis.
A psoriasis susceptibility locus defined as among linked members within a family has been identified. The locus is linked to an intron of the interleukin enhancer binding factor gene in some families, while being linked to an interleukin 2 gene in other families demonstrating a familial linked form of psoriasis. The locus identified may be further defined as being located distal to genetic marker D17S784 of human chromosome 17q. This locus does not demonstrate linkage with DNA markers within our flanking the HLA cluster of genes. A psoriasis susceptibility locus has also been observed close to the centromere of human chromosome 4. Both identified regions provide positive LOD scores with markers on chromosomes 17q and particularly two regions close to the ILF gene or the interleukin 8 gene. Methods of screening a family for psoriasis susceptibility using a defined familial psoriasis susceptibility locus are also disclosed. A cDNA capable of detecting a genetic polymorphism identifying the psoriasis susceptibility locus in families with a psoriasis afflicted member, and a process for preparing such a cDNA, are further disclosed. The molecular probes disclosed herein are also known to hybridize with the distal region of human chromosome 17q and with chromosome 4q, and therefore are useful for detecting a genetic lesion in chromosome 17q and 4q. A psoriasis gene related to familial forms of psoriasis is also disclosed. This gene maps to the distal end of human chromosome 17q and has close proximity or is within a gene encoding interleukin enhancer binding factor.
Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortexolone. The tetrahydrocortexolone serves to substantially prevent any significant increases in intraocular pressure which might otherwise by experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortexolone to a patient receiving such therapy.
Gastric cancer (GC) is the fourth cause of cancer-related death and the fifth most common diagnosed cancer worldwide with 1 million new cases per year. GC is mainly associated with a poor prognosis, highlighting the importance of its early detection. GC results from a multistep process starting from a gastric chronic inflammation preceding atrophic gastritis (AG), the development of preneoplasia (intestinal metaplasia (IM), dysplasia (Dys) and then cancer lesions. Presently, GC can only be diagnosed by endoscopy, which is an invasive, and costly method with its limits. Indeed, preneoplasia as Dys can escape endoscopic detection. Therefore, the discovery of blood-based biomarkers to identify the presence of gastric preneoplasia and/or cancer lesions at the earliest, at an asymptomatic stage, is of paramount interest. It is crucial not only for the early detection/prevention of individuals at risk of GC but also useful for patient follow-up to predict disease recurrence/outcome and to monitor treatment. Using plasma samples from patients at various stages of the GC cascade, we previously identified two signatures of 6 protein candidates to predict the presence of preneoplasia and GC lesions. Based on these data, the goal of this study is to further test and validate these different signatures, and to improve their predictive ability at the earliest stages of the GC cascade, taking into account the different types of gastric preneoplasia, IM and Dys, and their grade of severity. To achieve this goal, a large multicentric cohort of patients will be established including different groups of plasma samples covering the most complete panel of the type/grades of gastric preneoplasia as well as at early stages of GC. These plasma samples will be then used to measure the level of the different signature components using various method of analysis as immuno-based assays.
The invention discloses the pinecone chrysanthemum polysaccharide, its preparation method, pharmaceutical preparation with the pinecone chrysanthemum polysaccharide and its uses in curing all kinds of inflammations, improving immunologic functions, antivirus and antibiosis, especially the anti SARS medicament. It is extracted from the raw material of pinecone chrysanthemum with its total sugar content is between 75% and 95%, average molecular weight between 30,000 and 80,000. The monosackcharides in total sugar are composed of between 30% and 75% of dextrose, between 10% and 60% of fructose and between 5% and 20% of arabinose. The preparation method includes the following steps: boil the pinecone chrysanthemum and deposit it in the alcohol, dissolve the concentrated extracting solution got after boiling the pinecone chrysanthemum with polar solvent to get rid of the protein and other impurities. We deposit it with alcohol after getting rid of the polar solvent and collect the precipitatel. We get the pinecone chrysanthemum polysaccharide with its molecule weight between 3000 an d130000 after separating the precipitatel and get the powder of the pinecone chrysanthemum polysaccharide after further treatment. The pinecone chrysanthemum polysaccharide of the invention contains no other impurities, is used as medicine in the form of polysaccharide, reduces the dose, has specific curative effect, no side effects and stable quantity and is easy to control.
The invention provides composition for treating syphilis. The composition is used in the following way: (1), applying medicinal liquor; (2), taking a western medicine Xianfeng No.4 five pills once; (3), taking traditional Chinese medicine composition decoction. The traditional Chinese medicine composition is prepared from the following raw materials: rehmannia roots, moutan bark, Chinese thorowax roots, amur corktree bark, golden thread, baical skullcap roots, akebia stems, dutchmanspipe fruits, European verbena, gentian and virgate wormwood herbs. The raw materials are soaked in boiled water for 5 hours, decocted for 40 minutes and filtered, filtrate is taken once 30 minutes before breakfast, lunch and supper every day while hot, and seven times of dosage is taken as one treatment course. The composition is mainly prepared from pure traditional Chinese medicine components and has a high medicine property, the medicine efficacy can directly act on the body of a patient, treponema pallidum in blood is removed in the treatment process, besides, the body immunity of the patient can be improved, the composition takes effect quickly, the patient can feel better quickly, the composition is free of any side effect on the body after being taken, and syphilis cannot relapse. Medication results of 846 patients show that the total efficiency is 90% or higher.
PROBLEM TO BE SOLVED: To obtain a strong antioxidant component by extracting the sweet component from leaves of Stevia with water or hot water and obtaining an effective component from the resultant hydrophilic org. solvent extractant. SOLUTION: A highly sweet component contained in leaves of Stevia rebaudiana BERTONI, a plant of the family Compositae, is extracted with water or hot water at 5-100 deg.C if necessary at a pH adjusted to about 10 with lime, etc., and is used as a sweetening agent. The extraction residue, i.e., the Stevia leaves discharged after the above extraction, is again subjected to extraction with a specified amt. of a hydrophilic org. solvent selected from among methanol, ethanol, acetone, polyhydric alcohols, etc., at 5-120 deg.C, pref. 50-90 deg.C for 0.5-24 hr. Then, the extractant is filtered or subjected to spontaneous precipitation to separate the residue, if necessary concentrated and dried, and diluted with or redissolved in water, freed of impurities by the adsorption with an ion-exchange resin, concentrated, and dried, thus giving an antioxidant powder.
PURPOSE:To obtain an excellent cleaner composition for hair having improved shampoo function, maintaining glossy hair, containing an anionic activator, by blending the activator with a silicone derivative and a hydrocarbon-based oil component in a specific ratio. CONSTITUTION:0.1-40wt.% anionic activator (e.g. fatty acid soap) is blended with 0.1-25wt.% silicone derivative (e.g. dimethylpolysiloxane) and 0.1-30wt.% hydrocarbon-based oil component (e.g. liquid paraffin). In the blending, the weight ratio of the silicone derivative and the hydrocarbon-based oil compound is 50/1-1/30. Further the blend is properly mixed with well-known cleaner composition components such as surfactant, humectant, polymer substance, germicide and perfume and prepared to give the objective substance. The substance has excellent foaming and cleaning power, lightening physical damage undergoing brushing after drying, protects the hair and has excellent utility.
PURPOSE:An agent, containing D-cistenolic acid as an active ingredient, capable of exhibiting inhibitory action on blood platelet agglutination, useful for treating and preventing thrombosis and having high safety. CONSTITUTION:A remedy and preventive agent for thrombosis, containing D-cistenolic acid as an active ingredient. It is demonstrated that blood platelet plays an important role in formation of thrombi and directly participates in the establishment and development of atherosclerosis as a basic disease of thrombosis and it is established that a blood platelet agglutination inhibitor is used as an antithrombotic agent. An antipyretic agent, analgesic agent, anti- inflammatory agent, etc., e.g. aspirin, etc., have been used as the blood platelet agglutination inhibitor, but side effect thereof is frequently strong. The above- mentioned D-cistenolic acid is a component extracted from an extract of fishes and shellfishes, etc., has improved inhibitory action on blood platelet agglutination and high safety and is suitable for use in a long period. Thereby the agent is useful for treating extremital arterial thrombosis, deep venous thrombosis, etc., preventing atherosclerosis, thrombogenesis in artificial dialysis, replacement by artificial heart valves, etc.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic having moderate change of temperature on skin, giving comfortable thermesthesia to the skin, having the excellent persistence of generated heat temperature, having a good blood circulation- stimulating effect by adding a heat-generating substance coated with a silicone- based coating. SOLUTION: This thermal cosmetic contains (B) a heat-generating substance (for example, calcium dichloride) coated with (A) a silicone-based coating (for example, dimethylpolysiloxane). In the cosmetic, the component A is preferably used in an amount of 0.001-20 pts.wt. per pt.wt. of the component B. The heat- generating substance is coated with the coating, for example, by a method comprising heating the coating and subsequently mixing the heated coating with the heat-generating substance or by a method comprising dissolving or dispersing the coating in a solvent, mixing the solution or dispersion with the heat-generating substance and subsequently removing the solvent. The uses of the cosmetic include packs, gels and cosmetics.
Cardiovascular safety pharmacology and toxicology studies include vehicle control animals in most studies. Electrocardiogram data on common vehicles is accumulated relatively quickly. In the interests of the 3Rs principles it may be useful to use this historical information to reduce the use of animals or to refine the sensitivity of studies. We used implanted telemetry data from a large nonhuman primate (NHP) cardiovascular study (n = 48) evaluating the effect of moxifloxacin. We extracted 24 animals to conduct a n = 3/sex/group analysis. The remaining 24 animals were used to generate 1000 unique combinations of 3 male and 3 female NHP to act as control groups for the three treated groups in the n = 3/sex/group analysis. The distribution of treatment effects, median minimum detectable difference (MDD) values were gathered from the 1000 studies. These represent contemporary controls. Data were available from 42 NHP from 3 other studies in the same laboratory using the same technology. These were used to generate 1000 unique combinations of 6, 12, 18, 24 and 36 NHP to act as historical control animals for the 18 animals in the treated groups of the moxifloxacin study. Data from an additional laboratory were also available for 20 NHP. The QT, RR and QT-RR data from the three sources were comparable. However, differences in the time course of QTc effect in the vehicle data from the two laboratories meant that it was not possible to use cross-lab controls. In the case of historical controls from the same laboratory, these could be used in place of the contemporary controls in determining a treatment's effect. There appeared to be an advantage in using larger (≥18) group sizes for historical controls. These data support the opportunity of using historical controls to reduce the number of animals used in new cardiovascular studies.
OBJECTIVE: This study aimed to form astute deductions regarding the presentation, treatment and mortality of otogenic brain complications.
METHODS: A systematic literature search of four medical databases (PubMed, Embase, Web of Science and Scopus) was conducted. Studies associated with otogenic brain complications were considered eligible. Fixed- and random-effects model meta-analysis was developed to assess the proportion estimate for each outcome individually.
RESULTS: Twenty-eight studies, with 1650 patients in total, were included. In 66 per cent of patients there was a known history of chronic otitis media. The most common symptoms were purulent otorrhoea (84 per cent), headache (65 per cent) and otalgia (45 per cent). A brain abscess was observed in 49 per cent of patients, followed by meningitis (34 per cent) and sinus thrombosis (22 per cent). A combination of surgical and conservative therapy was chosen in 84.3 per cent of cases and the mortality rate approached 11.1 per cent.
CONCLUSION: Otogenic brain complications are a possibly life-threatening condition. Prompt imaging examination may set the final diagnosis and lead to an effective treatment.
According to one embodiment of the present invention, a system for monitoring medical events for adverse effects includes at least one processor. The processor may be configured to identify one or more medical events within patient medical information by applying first analytics to the medical information. The medical information may include unstructured information. The processor is further configured to determine adverse effects of the identified medical events and corresponding time intervals of occurrence by applying second analytics to medical reference information, wherein effect information includes the identified medical events, determined adverse effects, and corresponding time intervals of occurrence. In addition, the processor is configured to determine from the effect information any adverse effects for a patient and the corresponding time intervals of occurrence. Finally, the processor is configured to notify a user of the determined adverse effects prior to initiation of the corresponding time intervals of occurrence.
Pediatric heart transplant recipients receiving MMF will undergo study testing to measure MPA levels by the HPLC method and T-cell subsets by flow cytometry method. As standard of care they receive histological grading of routine endomyocardial biopsies using the International Society of Heart Lung Transplantation (ISHLT) grading scale. The data obtained from standard assessments will include medications, echocardiographic reports, pre-and post biopsy assessments/physical exams, hospital records for any inpatient hospitalization, and any laboratory assessments. Also, information will be collected on all patients which will be examined for tolerance and success (side effects and rejection) of immunosuppressive therapy.

In newly transplanted patients, study testing will occur at the same time as standard of care biopsies which are typically 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 8 months, 10 months, 12 months. If the patient has additional visits due to rejection or changes in immunosuppression, then more frequent study testing may be done per investigator preference. Previously transplanted patients will have study testing at the same time as their standard of care visits, usually annually.
As a result of clinical observations, a common practice is to inflate the cuff to a high and random mmHg value and start auscultation directly. Alternatively, many healthcare workers determine the moment when pulse beats disappear by palpation and increase this value by 30 mmHg without lowering the cuff and without taking a break for 1-2 minutes and start auscultation. In the literature, there is a similar technique called "one-step method". According to this technique, the sphygmomanometer is wrapped around the individual's arm and the stethoscope is placed in the ear. The brachial artery is then palpated and identified. The cuff is inflated up to 30 mmHg above the systolic blood pressure of the individual. The cuff is then depressurized to 2-3 mmHg/second. It is observed that many healthcare professionals and students use this technique today because it is more practical in terms of measurement time. However, it is thought that the step of "inflating the cuff up to 30 mmHg above the systolic blood pressure value of the individual" in the process steps of the technique is not reliable enough. It is thought that it may lead to erroneous results in capturing sudden blood pressure changes in the individual. In this context, it is thought that it would be more reliable to determine the value at the moment when the pulse is not felt with the palpation technique, add 30 mmHg to this value without interruption and without lowering the cuff and continue auscultation. At the same time, combining palpation and auscultation and continuing them consecutively will shorten the measurement time and provide a practical application.

It is aimed to measure blood pressure in approximately 202 healthy adults. The purpose and method of the study will be explained in detail to all participants included in the sample group. Participants will be allowed to rest for 15-30 minutes before blood pressure measurement. Blood pressure will be measured with two different techniques according to the order in which the participants are included in the study. The first participant's blood pressure will first be measured with the standard technique in the literature (with a break between palpation and auscultation). After a 60-second pause, blood pressure will be measured with the alternative recommended technique (palpation and auscultation combined). In the second participant, blood pressure will be measured first with the alternative recommended technique (combining palpation and auscultation). After a 60-second break and with the arm in the same position, blood pressure will be measured with the standard technique in the literature (with a break between palpation and auscultation). The cross-over method will be applied as possible differences between measurement times should be taken into account.